Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vir Biotechnology Inc V.VIR


Primary Symbol: VIR

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.


NDAQ:VIR - Post by User

Comment by Redearth7on Nov 11, 2019 10:58am
339 Views
Post# 30335401

RE:RE:RE:RE:RE:RE:RE:RE:RE:Experion Wellness = 130 followers on twitter

RE:RE:RE:RE:RE:RE:RE:RE:RE:Experion Wellness = 130 followers on twitter You have to read what The Sloutch releases  PARC NFM. He is very direct with shareholders it seems on loosing their cash. This company is being touted as a slow growth downward dog marijuana company.  That is a not a good investment. Now that everything is legal, speculation doesnt make a company rise, revenue will. This company is 1 year into legalization, is seeing a revenue increase every quarter - but less then what I made shoveling sidewalks last year, part time and just completed renovations that will uptick production by 50 percent - 50 percent of nothing or close to...is still nothing - or close to.  I personally believe there is more money in extracts. When Experion absorbed EFX labs, it also absorbed  its two piece pill patent. You should be thinking years instead of months. This company won’t last years at the revenue they earn and what is being spent on their executive team...gulp and gulp!!!  Like I said, the next few quarters will reflect the newly legalized oils and extracts sector.  Ya and 98,000000 plus shares, you go on keep drinking the Kool-Aid.

<< Previous
Bullboard Posts
Next >>